Literature DB >> 22053942

Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group.

Justin A Chen1, George I Papakostas, Soo Jeong Youn, Lee Baer, Alisabet J Clain, Maurizio Fava, David Mischoulon.   

Abstract

OBJECTIVE: To reanalyze data from a 2002 study by the Hypericum Depression Trial Study Group to determine whether patients who believed they were receiving active therapy rather than placebo obtained greater improvement, independent of treatment.
METHOD: Three hundred forty adults with major depressive disorder (according to the Structured Clinical Interview for DSM-IV) and baseline scores of ≥ 20 on the 17-item Hamilton Depression Rating Scale (HDRS-17) were randomized to Hypericum perforatum 900-1,500 mg/d, sertraline 50-100 mg/d, or placebo and were asked to guess their assigned treatment after 8 weeks. This reanalysis of data was performed from October 1, 2009, to April 15, 2011. The intent-to-treat sample included 207 subjects (mean age = 44 years) who had (1) at least 1 postbaseline visit; (2) adherence data based on serum levels of hyperforin, sertraline, and desmethylsertraline; and (3) guess data. Univariate factorial analysis of variance was used to determine whether treatment assignment affected clinical improvement according to HDRS-17 score and whether this effect was moderated by patient guess of sertraline, Hypericum, or placebo. Analysis of covariance was used to determine whether side effects mediated improvement in the context of patient guess and assigned treatment. χ₂ analyses compared response rates (≥ 50% decrease in HDRS-17 score) between the guess groups and between the treatment groups within each guess group.
RESULTS: Assigned treatment had no significant effect on clinical improvement (P = .65), but patient guess was significantly associated with improvement (P < .001), and treatment and guess interacted significantly (P = .005). Among subjects who guessed placebo, clinical improvement was small and did not differ significantly across treatments. Among subjects who guessed Hypericum, improvement was large and did not differ significantly across treatments. Among subjects who guessed sertraline, those who received placebo or sertraline had large improvements, but those who received Hypericum had significantly less improvement (P < .001). Similar findings were obtained for response rates.
CONCLUSIONS: Patient beliefs regarding treatment may have a stronger association with clinical outcome than the actual medication received, and the strength of this association may depend upon the particular combination of treatment guessed and treatment received. © Copyright 2011 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22053942     DOI: 10.4088/JCP.10m06453

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

1.  Taking the depressed "person" into account before moving into personalized or precision medicine.

Authors:  Koen Demyttenaere
Journal:  World Psychiatry       Date:  2016-10       Impact factor: 49.548

Review 2.  The placebo response in medicine: minimize, maximize or personalize?

Authors:  Paul Enck; Ulrike Bingel; Manfred Schedlowski; Winfried Rief
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

Review 3.  Building an evidence base in complementary and integrative healthcare for child and adolescent psychiatry.

Authors:  Emmeline Edwards; David Mischoulon; Mark Rapaport; Barbara Stussman; Wendy Weber
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2013-05-17

4.  A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder.

Authors:  David Mischoulon; Lawrence H Price; Linda L Carpenter; Audrey R Tyrka; George I Papakostas; Lee Baer; Christina M Dording; Alisabet J Clain; Kelley Durham; Rosemary Walker; Elizabeth Ludington; Maurizio Fava
Journal:  J Clin Psychiatry       Date:  2014-04       Impact factor: 4.384

5.  The placebo effect in psychiatric practice.

Authors:  Michael H Bernstein; Walter A Brown
Journal:  Curr Psychiatr       Date:  2017-11

6.  Association between physician beliefs regarding assigned treatment and clinical response: re-analysis of data from the Hypericum Depression Trial Study Group.

Authors:  Justin A Chen; Sagar Vijapura; George I Papakostas; Susannah R Parkin; Daniel Ju Hyung Kim; Cristina Cusin; Lee Baer; Alisabet J Clain; Maurizio Fava; David Mischoulon
Journal:  Asian J Psychiatr       Date:  2014-12-09

7.  Side effects can enhance treatment response through expectancy effects: an experimental analgesic randomized controlled trial.

Authors:  Chantal Berna; Irving Kirsch; Sean R Zion; Yvonne C Lee; Karin B Jensen; Pamela Sadler; Ted J Kaptchuk; Robert R Edwards
Journal:  Pain       Date:  2017-06       Impact factor: 6.961

8.  Psychiatrists' Attitudes Toward Non-Pharmacologic Factors Within the Context of Antidepressant Pharmacotherapy.

Authors:  Sagar Vijapura; Johannes A C Laferton; David Mintz; Ted J Kaptchuk; David Wolfe
Journal:  Acad Psychiatry       Date:  2015-12-08

9.  Follow up of patients who start treatment with antidepressants: treatment satisfaction, treatment compliance, efficacy and safety.

Authors:  Jesús López-Torres; Ignacio Párraga; José M Del Campo; Alejandro Villena
Journal:  BMC Psychiatry       Date:  2013-02-20       Impact factor: 3.630

10.  Mood disorders and complementary and alternative medicine: a literature review.

Authors:  Naseem Akhtar Qureshi; Abdullah Mohammed Al-Bedah
Journal:  Neuropsychiatr Dis Treat       Date:  2013-05-14       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.